Pipeline Progress - BINHUI BIOPHARM

Clinical Trials

Your current location：

Home > Clinical Trials > Pipeline Progress

Pipeline

Process

Candidates

Indication

Pre-clinical

IND

Dose Escalation (Phase I)

Dose Extension (Phase II)

Pivotal Study
(Phase III)

Oncolytic virus

BS001（CN）

Melanoma

GBM

mCRC

Others

BS001(US)

Melanoma with αPD-1 failure

BS001 combo with αPD-1 (CN)

mCRC

Sarcoma

BS006（CN）

Solid tumors（IIT)

BS006（US）

Solid tumors

Cell therapy

VAK（CN）

Malignant pleural and abdominal effusions（IIT)

VAK（US）

Malignant pleural and abdominal effusions（IIT)

Note：BS001:oHSV2^hGM-CSF，also named OH2 injection；BS006: oHSV2^CD3-PD-L1; BS008 (Cocktail): BS001+BS006

Research

Center

Nansha Islands

Introduction to Clinical Centers

The clinical trials of oncolytic type II herpes simplex virus OH2 injection (BS001) monotherapy/combination therapy have been conducted in 20+ research centers (hospitals) in China, 400+ subjects were enrolled for various indications.

BD Tel.：0086-027-87326962

Info Disclosure Tel.：0086-027-87700600

Office Address：D3-4 of OVU Technology City, Gedian Development Zone, Ezhou, Hubei Province

Registered Address：No. 666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan

Website：www.binhui-bio.com

BD e-mail：BD@binhui-bio.com

Info Disclosure e-mail：binhui@binhui-bio.com

About Us
Company Profile Management Team Product Pipelines Contact Us
Products and Services
Service Advantages Viral Vector Nucleic acid Products Protein Products Antibody Preparation Cell Therapy Cell Line Construction Testing Services Consultation Services Reagents and Kits Equipment
R&D platform
Viral Vector Platform Nucleic Acid Platform Protein Platform Cell Therapy Platform
Clinical trials
Pipeline Progress Research Center

Please scan the code to follow our account

鄂ICP备16007335号-1

Legal Terms

Partners

Website development: Lucky Coordinates

Purchase

Top